Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Mar 25;17(6):756-767.
doi: 10.1016/j.jcin.2023.12.018. Epub 2024 Feb 21.

A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries: The REPLICA-EPIC18 Study

Oriol Rodriguez-Leor  1 , Ana Belen Cid-Alvarez  2 , Maria Lopez-Benito  3 , Nieves Gonzalo  4 , Victoria Vilalta  5 , Jose Antonio Diarte de Miguel  6 , Leticia Fernandez López  7 , Alfonso Jurado-Roman  8 , Alejandro Diego  9 , Juan Francisco Oteo  10 , Carlos Cuellas  3 , Ramiro Trillo  2 , Alejandro Travieso  4 , Fernando Alfonso  11 , Xavier Carrillo  5 , José Miguel Vegas-Valle  12 , Carlos Cortes-Villar  6 , Isaac Pascual  13 , Juan Francisco Muñoz Camacho  7 , Xacobe Flores  14 , Silvio Vera-Vera  8 , Jose Moreu  15 , Gilles Barreira de Sousa  9 , David Martí  16 , Jesus Jimenez-Mazuecos  17 , Monica Fuertes  18 , Raymundo Ocaranza  19 , Jose Maria de la Torre Hernandez  20 , Fernando Lozano  21 , Santiago G Solana Martinez  22 , Josep Gómez-Lara  23 , Armando Perez de Prado  3 ; REPLICA-EPIC18 Investigators
Collaborators, Affiliations
Free article
Multicenter Study

A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries: The REPLICA-EPIC18 Study

Oriol Rodriguez-Leor et al. JACC Cardiovasc Interv. .
Free article

Abstract

Background: Intravascular lithotripsy (IVL) has demonstrated effectiveness in the treatment of calcified lesions in selected patients with stable coronary disease.

Objectives: The authors sought to assess the performance of coronary IVL in calcified coronary lesions in a real-life, all comers, setting.

Methods: The REPLICA-EPIC18 study prospectively enrolled consecutive patients treated with IVL in 26 centers in Spain. An independent core laboratory performed the angiographic analysis and event adjudication. The primary effectiveness endpoint assessed procedural success (successful IVL delivery, final diameter stenosis <20%, and absence of in-hospital major adverse cardiovascular events [MACE]). The primary safety endpoint measured freedom from MACE at 30 days. A predefined substudy compared outcomes between acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients.

Results: A total of 426 patients (456 lesions) were included, 63% of the patients presenting with ACS. IVL delivery was successful in 99% of cases. Before IVL, 49% of lesions were considered undilatable. The primary effectiveness endpoint was achieved in 66% of patients, with similar rates among CCS patients (68%) and ACS patients (65%). Likewise, there were no significant differences in angiographic success after IVL between CCS and ACS patients. The rate of MACE at 30 days (primary safety endpoint) was 3% (1% in CCS and 5% in ACS patients [P = 0.073]).

Conclusions: Coronary IVL proved to be a feasible and safe procedure in a "real-life" setting, effectively facilitating stent implantation in severely calcified lesions. Patients with ACS on admission showed similar angiographic success rates but showed a trend toward higher 30-day MACE compared with patients with CCS. (REPLICA-EPIC18 study [Registry of Coronary Lithotripsy in Spain]; NCT04298307).

Keywords: acute coronary syndrome; coronary artery calcification; intravascular lithotripsy.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The study sponsor, Fundación EPIC, has received an institutional research grant from Shockwave Medical (Santa Clara, California, USA) to cover the design and maintenance costs of the electronic case report form. Shockwave Medical has had no influence on the study design or protocol in any respect. Shockwave Medical was not involved in the conduct of the study, including inclusion, follow-up, data collection, analysis, interpretation of results, drafting, and final approval of the protocol, nor in the genesis of this paper. Dr Rodriguez-Leor has received speaker honoraria and consulting fees from Medtronic and World Medica. Dr Pérez de Prado has received speaker honoraria and consulting fees from iVascular, Boston Scientific, Terumo, B. Braun, and Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

Associated data